Back to results
US 2025/0084172 A1Published application
Antigen binding proteins
Assignees23andMe, Inc., GlaxoSmithKline Intellectual Property (No.3) Limited
InventorsJoel Benjamin, Shashank Bharill, I-Ling Chen, Yu Chen, Wei-Jen Chung, Zahra Bahrami Dizicheh, Germaine Fuh, Patrick Koenig, Yujie Liu, Mauro Poggio, Shruti Yadav, Ping-Chiao Tsai, Claus Spitzfaden
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.
Claims34
A ULBP6 binding protein comprising:
- a) (i) any one or a combination of CDRs selected from CDRH1, CDRH2, CDRH3 from SEQ ID NOs:
- 16-19, and/or CDRL1, CDRL2, CDRL3 from SEQ ID NOs:
- 26-29;
- or (ii) a CDR variant of (i) wherein the variant has 1, 2, or 3 amino acid modifications;
- or
- b) a VH region comprising a sequence at least 80% identical to the sequence of any one of SEQ ID NOs:
- 21-24;
- and/or a VL region comprising a sequence at least 80% identical to the sequence of any one of SEQ ID NOs:
- 31-34.
6 more elements
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.